

Thursday: Lynch syndrome / Hyperplastic polyposis

07:00 Registry Session

Chairpersons: Terri Berk

Plenary session 1: Basic Science

Chairpersons: Mike Woods, Rolf Sijmons

08:00	Functional PMS2-PMS2CL-"hybrid"-alleles containing pseudogene-specific sequence variants account for a third of all alleles	Katharina Wimmer
08:10	T cell immune response against frameshift-induced neopeptides in HNPCC	Matthias Kloor
08:20	Humoral immune response against tumor-specific frameshift peptides in Hereditary Nonpolyposis Colorectal Cancer	Miriam Reuschenbach
08:30	Molecular mechanisms underlying the differential expression of HLA class II antigens in microsatellite unstable colorectal carcinoma	Sara Michel
08:40	Autosomal dominant form of MLH1 epimutation segregates with a genetic haplotype in a three-generation HNPCC family	Megan Hitchins
08:50	Deletion of the 3' exons of TACSTD1 causes Hereditary Nonpolyposis Colorectal Cancer with MSH2 gene promoter methylation	Suet Yi Leung
09:00	A novel cause of Lynch Syndrome: heritable somatic methylation of MSH2 due to deletion of the 3' exons of the upstream gene	Marjolijn Ligtenberg
09:10	A frequent germline EPCAM deletion causes Lynch Syndrome by hypermethylation of the MSH2 promotor	Renée C. Niessen
09:20	General discussion	

09:30 – 10:00 hrs Coffee break

10:00 Breaking news lecture

CAPP2 and Beyond
The Colon Cancer Stem Cell and Aspirin
Introduction by John Baron

John Burn
Riccardo Fodde

Plenary session 2: Clinical identification, cancer risk, modifiers

Chairpersons: Malcolm Dunlop, Maurizio Genuardi

10:30	Identification of novel genes involved in colorectal cancer predisposition	Ramprasath Venkatachalam
10:40	Development and validation of a prediction model to estimate gene-specific risk in Lynch Syndrome	Fay Kastrinos
10:50	Lynch syndrome cancer risks for MSH6 mutation carriers	Mark A. Jenkins
11:00	Estimation of extra-colonic cancer risks in MLH1, MSH2 and MSH6 mutation carriers	Christoph Engel
11:10	Haemochromatosis HFE gene polymorphisms as potential modifiers of Hereditary Nonpolyposis Colorectal Cancer risk and onset age	Rodney J. Scott
11:20	Modifiers of colorectal cancer risk in Lynch Syndrome	Juul Wijnen
11:30	Overweight and the development of colorectal tumours in Lynch Syndrome mutation carriers	Akke Botma
11:40	Germline mutations in MMR-genes show association with prostate cancer	Pål Møller
11:50	General discussion	

12:00 – 13:00 hrs Lunch break & Posters

12:00 – 13:00 hrs Council meeting

13:00	Warthin lecture Human Variome Project and recent developments InSiGHT and recent developments Introduction by Tom Weber	Richard Cotton Johan den Dunnen Finlay Macrae
--------------	--	--

Plenary session 3: Lynch Syndrome, Hyperplastic Polyposis

Chairpersons: Jukka Pekka Mecklin, Hans Vasen

14:00	Ten years after mutation testing for Lynch Syndrome: cancer incidence and outcome	Heikki J. Järvinen
14:10	The outcome of longterm surveillance of Lynch Syndrome families in the Netherlands	Hans Vasen
14:20	Natural history of Amsterdam patients following colorectal cancer resection	Matthew F. Kalady
14:30	Serological markers in evaluation of individual risk of gastric cancer among mutation carriers in Lynch Syndrome	Jukka-Pekka Mecklin
14:40	Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch Syndrome kindreds	Eli Marie Grindedal
14:50	Family history of colorectal cancer is inversely related to polyp count in individuals with multiple serrated polyps	Joanne Young
15:00	Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: a multicentre cohort study	K.S. Boparai
15:10	Narrow-band imaging improves the detection of polyps in patients with hyperplastic polyposis syndrome: a prospective randomized study	K.S. Boparai
15:20	General discussion	

15:30 – 16:00 hrs Coffee Break

16:00 IH – Ten years after
Chairpersons Steve Thibodeau, Ian Frayling

16:00	Mismatch repair gene protein expression in young patients with colorectal cancer: the eight year Auckland experience	Susan Parry
16:10	Interobserver variability in the interpretation of immunohistochemical Mismatch Repair Protein staining	Louise Klarskov
16:20	Initial experiences of the UK national external quality assessment scheme for immunocytochemistry of DNA mismatch repair proteins.	Ian M Frayling

16:30 Meera Khan Lecture
"Development and Status of the German HNPCC Consortium"
Introduction by Gabriela Möslein

Peter Propping
